CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,016 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03643211
NCT03643211N/ACompleted

XELJANZ(REGISTERED) TABLETS 5 MG SPECIAL INVESTIGATION(INVESTIGATION OF LONG-TERM USE IN PATIENTS WITH ULCERATIVE COLITIS)

Pfizer·observational·Posted Aug 22, 2018·Updated Oct 8, 2024

In Brief

An observational study for Ulcerative Colitis. Completed, enrolled 2,016 participants across 1 site.

Detailed Summary

Secondary data collection study: safety and effectiveness of Xeljanz in UC patients under Japanese medical practice

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 22, 2018
Enrollment StartJun 8, 2018
Primary CompletionNov 10, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 7.9 years ago